XML 25 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Accrued Expenses
12 Months Ended
Dec. 31, 2017
Payables and Accruals [Abstract]  
Accrued Expenses
Accrued Expenses
 
Accrued expenses and other current liabilities consisted of the following:
 
As of
 
December 31, 2017
 
December 31, 2016
Bonus
$
2,538,340

 
$
2,357,194

Deferred revenue-R&D for TPOXX® intravenous formulation
1,255,318

 

Professional fees
381,980

 
481,641

Vacation
328,588

 
262,664

Other
977,353

 
1,483,253

Accrued expenses and other current liabilities
$
5,481,579

 
$
4,584,752